{"id":"igovomab","rwe":[],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IGOVOMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:36:48.705399+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:36:53.889939+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IGOVOMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:36:54.249264+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Mucin-16 binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:36:55.316595+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109036/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:36:54.951616+00:00"}},"allNames":["igovomab"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Igovomab is a murine monoclonal antibody that binds to a specific antigen, triggering an immune response that can help eliminate targeted cells or substances."},"commercial":{},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=igovomab","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:37:36.014330","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:36:56.581554+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"igovomab","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL2109036"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","brandName":"IGOVOMAB","companyName":"","companyId":"","modality":"Monoclonal antibody","firstApprovalDate":"1996","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":null,"brand_name_local":"Indimacis 125","application_number":"EMEA/H/C/000065"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Indimacis 125","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:36:56.581554+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}